Large bolus dose vs. continuous infusion of cisatracurium during hypothermic cardiopulmonary bypass surgery

Background and objective: We investigated whether a high bolus dose of cisatracurium (8× ED95) given at induction can provide muscle relaxation for the major part of a cardiac procedure with hypothermic cardiopulmonary bypass, avoid important postoperative residual curarization and cause no waste of product. Methods: Twenty patients were randomly assigned either to Group 1 (n = 10) or Group 2 (n = 10). Those in Group 1 were given cisatracurium in a high bolus dose (0.4 mg kg−1). Those in Group 2 received cisatracurium 0.1mg kg−1 at induction followed after 30 min by a continuous infusion of cisatracurium. As an escape medication in case of patient movement, a bolus dose of cisatracurium 0.03 mg kg−1 was given. Results: In Group 1 (large cisatracurium bolus dose), the clinical duration of effect (until T1/T0 = 25%) was 110 min. Six of 10 patients in Group 1 required additional boluses of cisatracurium intraoperatively. Four of these six had received an additional bolus near the end of surgery and had a train‐of‐four (TOF) ratio = 0 at the end. The other four patients in Group 1 had a final TOF ratio >0.9. In Group 2 (continuous cisatracurium infusion), only two patients had a TOF ratio >0.9 at the end of surgery, no patient moved and none received additional boluses. The total amount of cisatracurium used in the bolus and infusion Groups was 34.5 ± 7.8 and 21.3 ± 5.7 mg, respectively (P = 0.0004). Conclusions: For continued neuromuscular block during hypothermic cardiac surgery, a high bolus dose of cisatracurium appears to be safe, although it is not an alternative to a continuous infusion, as its neuromuscular blockade does not cover the intraoperative period and a high incidence of movements occurs. In the patients who received a high bolus dose of cisatracurium, postoperative residual curarization appeared after additional boluses had been given. The consumption of cisatracurium by high bolus was significantly greater than with continuous infusion.

[1]  M. Struys,et al.  Postoperative residual curarization with cisatracurium and rocuronium infusions. , 2002, European journal of anaesthesiology.

[2]  J. Hendrickx,et al.  Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass. , 2000, British journal of anaesthesia.

[3]  P. White,et al.  Reversal of neuromuscular blockade. , 1998, Anesthesia and analgesia.

[4]  D. Rosen,et al.  Elimination of drugs and toxins during cardiopulmonary bypass. , 1997, Journal of cardiothoracic and vascular anesthesia.

[5]  J. Wierda,et al.  Effects of hypothermic cardiopulmonary bypass on the pharmacodynamics and pharmacokinetics of rocuronium. , 1995, Journal of cardiothoracic and vascular anesthesia.

[6]  D. Reich,et al.  A Two-Center Comparison of the Cardiovascular Effects of Cisatracurium (Nimbex Trademmark) and Vecuronium in Patients with Coronary Artery Disease , 1995, Anesthesia and analgesia.

[7]  R. Welch,et al.  The in vitro degradation of cisatracurium, the R, cis‐R′‐isomer of atracurium, in human and rat plasma , 1995, Clinical pharmacology and therapeutics.

[8]  C. Lien,et al.  The Clinical Neuromuscular Pharmacology of 51W89 in Patients Receiving Nitrous Oxide/Opioid/Barbiturate Anesthesia , 1995, Anesthesiology.

[9]  E. Mortier,et al.  Cardiopulmonary Bypass and the Pharmacokinetics of Drugs , 1989 .

[10]  B. Walton,et al.  Use of atracurium in cardiac surgery involving cardiopulmonary bypass with induced hypothermia. , 1984, British journal of anaesthesia.

[11]  E. Mortier,et al.  Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. , 1989, Clinical pharmacokinetics.